Skip to content | Change text size
 

A/Prof Christopher J. H. Porter

Associate Professor in Pharmaceutics; Associate Dean Research

Associate Professor Chris Porter
BPharm, PhD, Univ. Nottingham

Phone: +61 3 9903 9649
Fax: +61 3 9903 9583
email: Chris.Porter@pharm.monash.edu.au

General Research Interests

  • Drug Delivery to the Lymphatic System
  • Factors Affecting Oral Drug Absorption
  • Intracellular Drug Disposition

Current Research Areas

  • Formulation approaches to enhance drug absorption after oral administration
  • Factors regulating absorption, metabolism and intestinal lymphatic transport of lipophilic compounds
  • Drug interactions with intracellular binding proteins
  • Dendrimer-based drug delivery

Recent Publications

  1. Kaminskas, L.M., Boyd, B.J., Karellas, P., Krippner, G.Y., Lessene, R., Kelly, B., Porter, C.J.H.  The impact of molecular weight and PEG chain length on the systemic pharmacokinetics of PEGylated poly-L-lysine dendrimers. (2008) Molecular Pharmaceutics, 5(3), 449-463.
  2. Pouton, C.W., Porter, C.J.H. Formulation of lipid-based delivery systems for oral administration: materials, methods and strategies. (2008) Advanced Drug Delivery Reviews 60, 625-637.
  3. Trevaskis, N.L., Charman, W.N., Porter, C.J.H. Lipid-based delivery systems and intestinal lymphatic drug transport: A mechanistic update (2008) Advanced Drug Delivery Reviews 60, 702-716.
  4. Porter, C.J.H, Pouton, C.W., Cuine, J.F., Charman, W.N. Enhancing intestinal drug solubilisation using lipid-based delivery systems. (2008) Advanced Drug Delivery Reviews 60, 673-691.
  5. Cuine, J.F.  McEvoy, C.L., Charman, W.N., Pouton, C.W., Edwards, G.A., Benameur, H., Porter, C.J.H. Evaluation of the impact of surfactant digestion on the bioavailability of danazol after oral administration of lipidic self-emulsifying formulation to dogs (2008) Journal of Pharmaceutical Sciences 97(2), 995-1012.
  6. Katneni, K., Charman, S.A., Porter, C.J.H. Use of plasma proteins as solubilizing agents in in vitro permeability experiments: correction for unbound drug concentration using the reciprocal permeability approach. (2008) Journal of Pharmaceutical Sciences 97(1) 209 - 224.
  7. Kaminskas, K., Boyd, B., Karellas, P., Henderson, S., Giannis, M., Krippner, G., Porter, C.J.H. Impact of surface derivatization of poly-L-lysine dendrimers with anionic aryisulfonate or succinate groups on intravenous pharmacokinetics and disposition. (2007) Molecular Pharmaceutics, 4(6), 949-961.
  8. Kota, J., Machavaram, K., McLennan, D., Edwards, G., Porter, C.J.H., Charman, S.A. Lymphatic absorption of subcutaneously administered proteins: influence of different injection sites on the absorption of darbepetin alfa using a sheep model. (2007) Drug Metabolism and Disposition 35(12), 2211-2217
  9. Kossena, G., Charman, W.N., Wilson, C., O'Mahony, B., Lindsay, B., Hempenstall, J., Davison, C., Crowley, P., Porter, C.J.H. Low dose lipid formulations: effects on gastric emptying and biliary secretion (2007) Pharmaceutical Research 24(11), 2084-2096.
  10. Boyd, B.J., Khoo, S.M., Whittaker, D.V., Davey, G., Porter, C.J.H. A lipid-based liquid crystalline matrix that provides sustained release and enhanced oral bioavailability for a model poorly water soluble drug in rats. (2007) International Journal of Pharmaceutics, 340, 52-60.
  11. Katneni, K., Charman, S.A., Porter, C.J.H. Impact of Cremaphor-EL and Polysorbate-80 on digoxin permeability across rat jejunum: delineation of thermodynamic and transporter related events using the reciprocal permeability approach. (2007) Journal of Pharmaceutical Sciences, 96(2) 280-293.
  12. Velkov, T., Horne, J., Laguerre, A., Jones, E., Scanlon, M.J., Porter, C.J.H. Examination of the role of intestinal fatty acid-binding protein in drug absorption using a parallel artificial membrane permeability assay. (2007) Chemistry & Biology, 14, 453-465.
  13. Cuine, J.F., Charman, W.N., Pouton, C.W., Edwards, G.A., Porter, C.J.H. Increasing the proportional content of surfactant (Cremophor EL) relative to lipid in self-emulsifying lipid-based formulations of danazol reduces oral bioavailability in beagle dogs. (2007) Pharmaceutical Research, 24(4), 748-757
  14. Porter, C.J.H, Trevaskis, N.L., Charman, W.N. Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs (2007) Nature Reviews Drug Discovery, 6(14), 231-248.
  15. Porter, C.J.H. Lipid-based delivery systems for poorly water soluble drugs: biopharmaceutical implications (2006) European Journal of Pharmaceutical Sciences 28, S8.
  16. Trevaskis, N., Porter, C.J.H., Charman, W.N. Short Communication: An examination of the interplay between enterocyte-based metabolism and lymphatic drug transport in the rat. (2006) Drug Metabolism and Disposition. 34, 729-733.
  17. Holm, R,. Porsgaard, T., Porter, C.J.H., Hoy, C.E., Edwards, G., Lullertz, A., Kristensen, H., Charman, W.N. Lymphatic fatty acids in canines dosed with pharmaceutical formulations containing structured triacyglycerols. (2006) European Journal of Lipid Science and Technology, 108, 714-722.
  18. Katneni, K., Charman, S.A. and Porter, C.J.H. Impact of the cremophor-EL and polysorbate-80 on gigoxin permeability across rat jejunum: delineation of thermodynamic and transport related events using the reciprocal permeability approach. (2206) Journal of Pharmaceutical Sciences, 58, 52-58.
  19. Katneni, K., Charman, S.A., Porter, C.J.H. Permeability assessment of poorly water-soluble compounds under solubilizing conditions: the reciprocal permeability approach. (2006) Journal of Pharmaceutical Sciences, 95(10), 2170-2185.
  20. Sek, L., Boyd, B.J., Charman, W.N., Porter, C.J.H. Examination of the impact of a range of Pluronic surfactants on the in-vitro solubilisation behaviour and oral bioavailability of lipidic formulations of atovaquone. (2006) Journal of Pharmacy and Pharmacology 58, 809-820.
  21. Boyd, B.J., Kaminskas, L., Karellas, P., Krippner, G., Lessene, R., Porter, C.J.H. Cationic ply-L-lysine dendrimers: pharmacokinetics, biodistribution and evidence for metabolism and bioresorption after intravenous administration to rats. (2006) Molecular Pharmaceutics, 3(5), 614-627.
  22. Trevaskis, N.L., Porter, C.J.H., Charman, W.N. An examination of the interplay between enterocyte-based metabolism and lymphatic drug transport in the rat. (2006) Drug Metabolism and Disposition 34(5), 729-733.
  23. Trevaskis, N.L., Lo, C.M., Ma, LL.Y., Tso, P., Irving, H., Porter, C.J.H., Charman, W.N.  An acute and coincident increase in FABP expression and lymphatic lipid and drug transport occurs during intestinal infusion of lipid-based drug formulations to rats. (2006) Pharmaceutical Research 23(8), 1786-1796.
  24. Trevaskis, N.L., Porter, C.J.H., Charman, W.N. The lymph lipid precursor pool is a key determinant of intestinal lymphatic drug transport. (2006) J. Pharmacol. Exp. Ther.   316, 881-891.
  25. Trevaskis, N.L., Porter, C.J.H., Charman, W.N. Bile increases intestinal lymphatic drug transport in the fasted rat. (2005) Pharm. Res. 22, 1863-70. 
  26. Velkov, T., Chuang, S., Prankerd, R., Sakellaris, H., Porter, C.J.H., Scanlon, M.J. An improved method for the purification of rat liver-type fatty acid binding protein from Escherichia coli.  (2005) Protein Express. Purif. 44, 23-31.
  27. Mehuys, E., Remon, J.P., Korst. A., Van Bortel, L., Mols, R., Augustijns, P., Porter, C.J.H., Vervaet., C. Human bioavailability of propranolol from a matrix-in-cylinder system with a HPMC-Gelucire® core. (2005) J. Controlled Release. 107,  523-536.
  28. McLennan, Porter, C.J.H., Charman, S.A. Subcutaneous drug delivery and the role of the lymphatics. (2005) Drug Discovery Today: Technologies, 2(1), 89-96.
  29. Velkov, T., Chuang, S., Wielens, J., Sakellaris, H., Charman, W.N., Porter, C.J.H., Scanlon, M.S.  The interaction of lipophilic drugs with intestinal fatty acid-binding protein. (2005) The Journal of Biological Chemistry, 280(18), 17769-17776.
  30. McLennan, D., Porter, C.J.H., Edwards, G.A., Martin, S. and Heatherington, A.C. Lymphatic absorption is the primary contributor to the systematic availability of epotein alfa following subcutaneous administration in sheep. (2005) The Journal of Pharmacology and Experimental Therapeutics 313(1), 313-345.
  31. McIntosh, M.P., Charman, W.N., Campbell, M., Porter, C.J.H. Influence of physicochemical properties on the patterns of association of a series of aliphatic esters of halofantrine with plasma lipoproteins. (2004) J. Cont. Rel., 95, 275-289.
  32. McIntosh, M.P., Batey, A.J., Coker, S.J., Porter, C.J.H., Charman, W.N. Evaluation of the impact of altered lipoprotein binding conditions on halofantrine induced QTc interval prolongation in an anaesthetised rabbit model.  (2004) J. Pharm. Pharmacol., 56, 69-77.
  33. Kossena, G.K., Charman, W.N., Boyd, B.J., Dunstan, D.E., Porter, C.J.H. Predicting drug solubilisation patterns in the gastrointestinal tract after administration of lipid based delivery systems: A phase diagram approach.(2004)  J. Pharm. Sci., 93, 332-348.
  34. Johnson, B.M., Charman, W.N., Porter, C.J.H. Influence of p-glycoprotein on the intestinal permeability and metabolism of verapamil: in vitro experimental and theoretical approaches. (2003) Drug Metab. Dispos., 31  1151-1160.
  35. Johnson, B.M., Charman, W.N., Porter, C.J.H. A kinetic evaluation of the absorption, efflux and metabolism of verapamil in the autoperfused rat jejunum. (2003) J. Pharmacol. Exp. Therap., 305, 151-158.
  36. Khoo, S.M. Shackleford, D., Porter, C.J.H. Edwards, G.A., Charman, W.N. Intestinal lymphatic transport of halofantrine occurs after oral administration of a unit dose lipid-based formulation to fasted dogs.(2003) Pharm. Res., 20,  1460-1465.
  37. Holm, R., Porter, C.J.H., Edwards, G.A., Mullertz, A., Kristensen, H.G., Charman, W.N. Examination of oral absorption and lymphatic transport of halofantrine in a triple cannulated canine model after administration in self-microemulsifying drug delivery systems (SMEDDS) containing structured triglycerides. (2003) Eur. J. Pharm. Sci., 20,  91-97.
  38. Shackleford, D.M., Fassen, W.A., Houwing, N., Lass, H., Edwards, G.A., Porter, C.J.H.,  Charman, W.N. The contribution of lymphatically transported testosterone undecanoate to the systemic exposure of testosterone after oral administration of two Andriol formulations in conscious lymph duct cannulated dogs.(2003)  J. Pharmacol. Exp. Ther., 306, 925-933.
  39. McLennan, D.N., Porter, C.J.H., Edwards, G.A., Brumm, M., Martin, S.W., Charman, S.A. A pharmacokinetic model to describe the lymphatic absorption of r-metHu-Leptin after subcutaneous injection to sheep. (2003) Pharm. Res., 20,  1156-1162 (CP contribution 15%).
  40. Shackleford, D.M., Porter, C.J.H., Charman, W.N. Does stereoselective lymphatic absorption contribute to the enantioselective pharmacokinetics of halofantrine in vivo? (2003) Biopharm.   Drug Dispos., 24,  153-157.